Skip to main content

Table 2 Serial changes in quality of life from baseline to the last follow-up visit

From: Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients

Variables

Mean Difference

Z

p-value

Satisfaction

Baseline & visit 1

3.78

-9.79

0.000*

Baseline & visit 2

6.11

-11.76

0.000*

Baseline & visit 3

7.92

-12.78

0.000*

Impact

Baseline & visit 1

2.32

-7.90

0.000*

Baseline & visit 2

3.95

-10.56

0.000*

Baseline & visit 3

5.20

-12.04

0.000*

Worry

Baseline & visit 1

1.68

-8.24

0.000*

Baseline & visit 2

2.83

-10.66

0.000*

Baseline & visit 3

3.70

-12.00

0.000*

Total

Baseline & visit 1

7.77

-9.87

0.000*

Baseline & visit 2

12.89

-11.78

0.000*

Baseline & visit 3

15.24

-11.62

0.000*

  1. The Wilcoxon Signed Ranks test is applied to observe the mean change in QoL from baseline to follow-up (Non-parametric data). *p < 0.05 is considered statistically significant. Z based on positive ranks